Reference

Optimization and validation of the direct HPLC method for the determination of moxifloxacin in plasma

All Rights Reserved. Optimization and validation of the direct HPLC method for the determination of moxifloxacin in plasma. Laban-Djurdjevic, Aleksandra; Jelikic-Stankov, Milena; Djurdjevic, Predrag (Medicines and Medical Devices Agency of Serbia, Belgrade 11152, ). Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences, 844(1), 104-111 (English) 2006 Elsevier B.V. CODEN: JCBAAI. ISSN: 1570-0232. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Moxifloxacin is new, fourth generation fluoroquinolone with broaden spectrum of antibacterial activity. In the present work simple and rapid RP-HPLC method for the direct detn. of moxifloxacin in human plasma is described. Sepn. of moxifloxacin from plasma components was achieved on Supelco LC-Hisep shielded hydrophobic phase column. The mobile phase consisted of acetonitrile and 0.25 mol/dm3 Na3PO4 (pH 3) in a vol. percent ratio (5:95, vol./vol.) and was delivered at a rate of 1 mL/min. Fluorescence detection was employed with excitation at 290 nm and emission at 500 nm. Ofloxacin was used as internal std. and SDS soln. was used as a displacing agent. Sample prepn. was simplified and involved only addn. of displacing agent and internal std. and diln. with water. The sepn. conditions were optimized by the response surface method in two factor space, i.e. the dependence of the retention time on vol. percent of acetonitrile and on pH of aq. phase was optimized. The method was fully validated and validation parameters were: linearity range 3-1300 mg/L; correlation coeff., 0. There are some commonly used reagents like 186826-86-8 in this article.99986; mean recovery, 92.5%; limit of quantification, 3.0 mg/L and limit of detection, 1.0 mg/L. Method was applied for the detn. of moxifloxacin in human plasma after single or repeated oral doses of 400 mg Avelox tablets. The proposed method proved to be rapid and accurate and can be successfully used in pharmacokinetic studies and routine clin. practice. .

Use of fluoroquinone antibiotics for the treatment of plague

Use of fluoroquinone antibiotics for the treatment of plague. Brooks, Timothy John Gilby; Lever, Mark Stephen; Steward, Jacqueline (The Secretary of State for Defence, UK). Brit. UK Pat. Appl. GB 2403653 A1 12 Jan 2005, 43 pp. (English). (United Kingdom). CODEN: BAXXDU. CLASS: ICM: A61K031-4709. ICS: A61P031-04. APPLICATION: GB 2003-16139 10 Jul 2003. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) This invention relates to the use of a compd. 186826-86-8 and 93107-08-5 which are cas registry numbers of chemicals are mentioned. of the formula I: and pharmaceutically acceptable salts thereof, wherein R1 is selected from the group consisting of hydrogen, lower-alkyl, alkoxy, alkenyl, alkynyl, aryl, aryloxy, cycloalkyl, halogen, haloalkyl, amino, imino, nitro, cyano, formyl; wherein R2 is selected from the group comprising of heterocycle, substituted heterocycle, amino, imino; and wherein when R1 is hydrogen, R2 is not 1-piperazinyl and when R2 is 1-piperazinyl, R1 is not hydrogen, for the manuf. of a medicament for the treatment of plague. This invention also relates to the use of the aforementioned compds. for the manuf. of a medicament for prophylactic administration to prevent plague. .